Founded with a mission to revolutionize the treatment of central nervous system diseases, ICB International focuses on developing innovative biomedicine solutions. The company's core vision is to bridge life-changing sciences into the brain, primarily through its SMART Molecule Technology Platform. This platform enables the delivery of therapeutic drugs across the blood-brain barrier, targeting neurodegenerative disorders like Parkinson’s and Alzheimer’s disease. ICB International also offers proprietary in vivo technologies for live imaging of Parkinson’s disease lesions in transgenic mice.

Notable figures affiliated with ICB International include leading scientists and biomedicine experts who have significantly contributed to the field. The company has attracted investments from prominent venture capital firms specializing in healthcare innovation. Key achievements include the successful demonstration of their technology's ability to deliver drugs across the blood-brain barrier and the development of advanced imaging techniques for neurodegenerative diseases. Overall, ICB International has made a substantial impact on the biomedicine landscape, offering promising new avenues for treating debilitating central nervous system disorders.